Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular and cellular mechanisms in allergic rhinitis patients treated with GRAZAX
2009-011453-41Phase 4Completed
- Sponsor
- ALK-Abelló
- Start
- May 2009
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of phleum pratense allergen extract in allergic rhinitis (AR) and allergic conjunctivitis (AC), sponsored by ALK-Abelló. Primary endpoints: Biological markers related to tolerance and clinical response to GRAZAX, Treatment tolerance over 3 years and 1 more. Started May 2009; status: completed.
02
Drugs
phleum pratense allergen extract
03
Conditions
allergic rhinitis (AR)allergic conjunctivitis (AC)
Beyond the preview
Go deeper on 2009-011453-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011453-41.